Beyfortus Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high rsv hospitalization rates in infants, unmet need for rsv prevention, monoclonal antibody advancements, neonatal care improvements, regulatory approvals.

The growth in the forecast period can be attributed to expanding newborn protection programs, increasing rsv awareness, public health funding growth, broader clinical guidelines adoption, long acting antibody innovation. Major trends in the forecast period include rising adoption of passive immunization, focus on rsv prevention in infants, single dose long acting antibody use, hospital based neonatal protection programs, seasonal rsv preparedness strategies.

The rising incidence of RSV cases is expected to drive the growth of the Beyfortus market going forward. Respiratory syncytial virus (RSV) is a highly contagious virus that primarily affects the respiratory tract, causing illnesses such as bronchiolitis and pneumonia, particularly in infants, young children, older adults, and immunocompromised individuals. The increasing incidence of RSV is largely due to reduced population immunity. Beyfortus supports respiratory health by providing targeted protection against RSV, making it suitable for infants, older adults, and immunocompromised patients. It reduces the risk of severe RSV infections, enhancing patient safety and public health outcomes. For example, in March 2025, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations, reported that RSV causes approximately 3.6 million hospitalizations and around 100,000 deaths each year among children under 5 years of age. Consequently, the rising incidence of RSV cases is contributing to the growth of the Beyfortus market.

The growth of the beyfortus market is also supported by increasing research and development activities. R&D involves the systematic exploration and creation of new knowledge, products, or technologies through research and experimentation. Rising R&D activities are driven by the demand for innovative solutions to address emerging health threats and improve treatment effectiveness. R&D benefits Beyfortus by fostering innovations in RSV prevention, enhancing its efficacy and safety for high-risk populations. It also supports broader adoption and improved patient outcomes. For example, in July 2025, Eurostat, a Luxembourg-based statistical agency, reported that total government budget allocations for research and development across the EU reached an estimated €127.91 billion in 2024, a 3.4% increase from €123.67 billion in 2023. Therefore, the growing research and development activities are contributing to the expansion of the beyfortus market.

Key companies in the beyfortus market are focusing on developing advanced therapies, such as monoclonal antibodies, to address widespread health threats and improve patient outcomes. Monoclonal antibodies are laboratory-produced proteins that mimic the immune system’s ability to target and neutralize harmful pathogens. For example, in July 2023, Sanofi SA, a France-based healthcare company, partnered with AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, and obtained marketing authorization from the European Commission for Beyfortus (nirsevimab). This single-dose, long-acting monoclonal antibody is designed to prevent RSV in newborns and infants by providing direct immunity and immediate protection throughout the RSV season.

Major companies operating in the beyfortus market are AstraZeneca plc, Sanofi SA.

North America was the largest region in the beyfortus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the beyfortus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the beyfortus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the beyfortus market by increasing costs associated with monoclonal antibody manufacturing and specialized biologic packaging. These impacts are most apparent in hospital neonatal units and public health programs across north america and europe. Higher import duties have affected procurement pricing for infant protection therapies. Supply chain coordination has also faced regulatory delays. At the same time, tariffs are encouraging local biologics production and strengthening long term pediatric healthcare supply resilience.

The beyfortus market research report is one of a series of new reports that provides beyfortus market statistics, including beyfortus industry global market size, regional shares, competitors with a beyfortus market share, detailed beyfortus market segments, market trends and opportunities, and any further data you may need to thrive in the beyfortus industry. This beyfortus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Beyfortus is a monoclonal antibody therapy (nirsevimab) developed to provide passive immunity against respiratory syncytial virus (RSV). It is indicated for the prevention of RSV lower respiratory tract infections in newborns and infants during their first RSV season, offering long-lasting protection with a single dose.

The primary uses of beyfortus include RSV prevention and infant care. RSV prevention involves measures to protect infants from respiratory syncytial virus, a major cause of severe respiratory illness in young children. The medication is distributed through hospitals, pharmacies, and public health programs.

The beyfortus market consists of sales of vaccines, allergy and over-the-counter medications, oncology drugs and central nervous system drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.